Physician profile
John A Bismayer
NPI 1902899214
$3,736.65
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $311 · 2021: $381 · 2022: $82.65 · 2023: $824 · 2024: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,052.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $488.61 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $441.42 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $366.64 | 2023-2024 | Imfinzi, Tagrisso |
| Abbvie INC. | $227.67 | 2023-2024 | Epkinly |
| Tesaro, INC. | $214.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $206.94 | 2019-2022 | |
| Janssen Biotech, INC. | $155.36 | 2019-2020 | |
| Glaxosmithkline, LLC. | $142.51 | 2021 | |
| Celgene Corporation | $125.00 | 2019 | |
| Emd Serono, INC. | $121.84 | 2023 | Tepmetko |
| Daiichi Sankyo INC. | $119.59 | 2020 | |
| Genzyme Corporation | $119.11 | 2019 | |
| Astellas Pharma US INC | $116.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.94 | 2019 | |
| Deciphera Pharmaceuticals INC. | $112.99 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $106.57 | 2020 | |
| Amgen INC. | $100.03 | 2019 | |
| Incyte Corporation | $100.00 | 2019 | |
| Verastem, INC. | $98.93 | 2019 | |
| Pfizer INC. | $87.80 | 2019 | |
| Exelixis INC. | $86.44 | 2019 | |
| Kyowa Kirin, INC. | $82.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bismayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.